-- インド証券取引所への木曜日の提出書類によると、アレンビック・ファーマシューティカルズ（NSE:APLLTD、BOM:533573）は、メトトレキサート注射剤の複数回投与バイアルおよび単回投与バイアルについて、米国食品医薬品局（US FDA）から最終承認を取得した。 メトトレキサート注射剤は、ホスピラ社の参照上場医薬品であり、葉酸アナログ代謝阻害剤で、悪性腫瘍の治療薬として適応がある。 また、関節リウマチ、多関節型若年性特発性関節炎、重症乾癬の治療にも用いられる。 同社の株価は、直近の取引で約2%上昇した。
Related Articles
Research
Rothschild & Co Redburn Upgrades Rollins to Buy From Neutral, Adjusts PT to $66 From $51.90
Rollins (ROL) has an average rating of overweight and mean price target of $65.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ROL
Research
Arete Research Upgrades Fortinet to Buy From Sell, Adjusts Price Target to $104 From $83
Fortinet (FTNT) has an average rating of hold and mean price target of $88.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$FTNT
Research
BNP Paribas Downgrades GE Vernova to Neutral From Outperform, Adjusts PT to $1,190 From $765
GE Vernova (GEV) has an average rating of overweight and mean price target of $1,179.31, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$GEV